OBJECTIVES: The goal of the present study was to explore additional evidence of validity of the Serbian version of the Central Sensitization Inventory (CSI), a patient-reported outcome measure of symptoms that have been found to be associated with central sensitization (CS). The CSI has been found to be psychometrically sound, and has demonstrated evidence of convergent and discriminant validity in numerous published studies and in multiple languages. METHODS: CSI data were collected from 399 patients with chronic pain who had various diagnoses and from 146 pain-free controls. In addition, the patient sample completed a battery of validated patient-reported outcome measures of sleep problems, cognitive problems, pain catastrophizing, pain-related fear-avoidance, decreased quality of life, and decreased perception of social support. Six patient subgroups were formed, with presumably different levels of CS (including those with fibromyalgia, multiple pain sites, and localized pain sites). RESULTS: Significant differences were found in total CSI scores among the controls and patient subgroups. Those with fibromyalgia and multiple pathologies scored highest and the control subjects scored lowest. Other patient-reported CS-related symptom dimensions were significantly correlated with total CSI scores. When the patients were divided into CSI severity subgroups (from subclinical to extreme), the severity of these other symptom dimensions increased with the severity of CSI scores. CONCLUSIONS: The current study successfully demonstrated additional evidence of the convergent and discriminant validity of the Serbian version of the CSI.
OBJECTIVES: The goal of the present study was to explore additional evidence of validity of the Serbian version of the Central Sensitization Inventory (CSI), a patient-reported outcome measure of symptoms that have been found to be associated with central sensitization (CS). The CSI has been found to be psychometrically sound, and has demonstrated evidence of convergent and discriminant validity in numerous published studies and in multiple languages. METHODS: CSI data were collected from 399 patients with chronic pain who had various diagnoses and from 146 pain-free controls. In addition, the patient sample completed a battery of validated patient-reported outcome measures of sleep problems, cognitive problems, pain catastrophizing, pain-related fear-avoidance, decreased quality of life, and decreased perception of social support. Six patient subgroups were formed, with presumably different levels of CS (including those with fibromyalgia, multiple pain sites, and localized pain sites). RESULTS: Significant differences were found in total CSI scores among the controls and patient subgroups. Those with fibromyalgia and multiple pathologies scored highest and the control subjects scored lowest. Other patient-reported CS-related symptom dimensions were significantly correlated with total CSI scores. When the patients were divided into CSI severity subgroups (from subclinical to extreme), the severity of these other symptom dimensions increased with the severity of CSI scores. CONCLUSIONS: The current study successfully demonstrated additional evidence of the convergent and discriminant validity of the Serbian version of the CSI.
Authors: Jani Mikkonen; Hannu Luomajoki; Olavi Airaksinen; Randy Neblett; Tuomas Selander; Ville Leinonen Journal: BMC Neurol Date: 2021-03-31 Impact factor: 2.474
Authors: Aleksandar Knežević; Petar Čolović; Milica Jeremić-Knežević; Čila Demeši-Drljan; Dušica Simić-Panić; Randy Neblett Journal: Int J Environ Res Public Health Date: 2021-06-28 Impact factor: 3.390
Authors: Ingrid Schuttert; Hans Timmerman; Kristian K Petersen; Megan E McPhee; Lars Arendt-Nielsen; Michiel F Reneman; André P Wolff Journal: J Clin Med Date: 2021-12-17 Impact factor: 4.241